Luvox was not pulled from the market over safety concerns. The original brand-name tablets were voluntarily withdrawn by their manufacturer, Solvay Pharmaceuticals, in 2002 after an FDA audit uncovered inaccuracies in the manufacturing documentation submitted as part of the drug’s approval. The FDA explicitly determined that the withdrawal was “not for reasons of safety or effectiveness,” and the active ingredient, fluvoxamine, remained available in generic form and was later re-introduced under a new brand formulation.
What Actually Happened in 2002
During a routine audit, the FDA found problems in the chemistry, manufacturing, and controls section of Solvay’s application for Luvox. This section of a drug application details how the medication is made, tested for purity, and stored. The inaccuracies raised questions about whether the manufacturing process at Solvay’s facility met federal standards.
Solvay had actually been placed under an “application integrity policy” by the FDA back in 1997, a designation reserved for companies where the agency has reason to doubt the reliability of data in their submissions. As part of the resulting consent agreement, Solvay voluntarily withdrew its approval for the Luvox tablets in May 2002. The company chose not to fight the issue or invest in correcting the documentation, effectively ending production of the original brand-name product.
The key detail: the FDA went out of its way to publish a Federal Register notice clarifying that Luvox’s withdrawal had nothing to do with the drug being unsafe or ineffective for treating obsessive-compulsive disorder. This distinction matters because when a drug is withdrawn for safety reasons, it can block future generic versions from being approved. The FDA wanted to make sure that wouldn’t happen here.
The Columbine Connection
Many people associate Luvox’s disappearance with the 1999 Columbine High School shooting, and the timing did overlap. An autopsy revealed that one of the gunmen, Eric Harris, had a therapeutic level of fluvoxamine in his system at the time of the attack. Families of five victims later sued Solvay Pharmaceuticals, claiming the company had not adequately warned Harris’s psychiatrist about side effects that could include impaired judgment.
The lawsuit and resulting media coverage undeniably damaged the Luvox brand. At the time, Luvox was already a relatively small player in the antidepressant market compared to drugs like Prozac and Zoloft. The negative publicity made an already modest commercial product even less appealing to defend. While Solvay’s official reason for withdrawal was the manufacturing documentation issue, the reputational damage almost certainly reduced any financial incentive to resolve those problems and keep the brand alive.
The Drug Came Back
Fluvoxamine never truly left the U.S. market. After the brand-name tablets were discontinued, generic versions of the immediate-release tablets remained available by prescription. Then in February 2008, the FDA approved Luvox CR, a controlled-release capsule formulation, under a completely new drug application with updated manufacturing data. Jazz Pharmaceuticals brought this version to market in 100 mg and 150 mg capsules, approved for maintenance treatment of OCD. Generic versions of the extended-release capsules followed, with FDA approval beginning in 2013.
Today, fluvoxamine is a fully available, FDA-approved medication. It carries the same boxed warning required of all antidepressants in its class regarding an increased risk of suicidal thinking and behavior in children, adolescents, and young adults. This warning applies to every SSRI, not just fluvoxamine, and was added across the board in the mid-2000s.
What Fluvoxamine Is Used For Now
Fluvoxamine’s only FDA-approved use is for obsessive-compulsive disorder. It belongs to the same class of medications as sertraline and fluoxetine (SSRIs), which work by increasing serotonin activity in the brain. Doctors sometimes prescribe it off-label for social anxiety disorder and depression, though these are not its approved indications in the U.S.
The drug gained renewed attention during the COVID-19 pandemic when researchers investigated whether it could prevent severe illness in people with early infections. A Phase 3 clinical trial enrolled 670 participants to test whether fluvoxamine, taken twice daily at doses up to 100 mg, could reduce the risk of clinical deterioration like hospitalization or dangerously low oxygen levels. While this generated significant media coverage and scientific debate, the FDA never approved fluvoxamine for COVID-19 treatment. Its approved use remains limited to OCD.
Why the Confusion Persists
The reason this question keeps getting searched is that “taken off the market” sounds alarming, and the real explanation is buried in FDA regulatory language that most people never encounter. When a drug disappears from pharmacy shelves, the natural assumption is that something was wrong with it. In Luvox’s case, the problem was paperwork and manufacturing oversight at one company’s facility, not the medication itself. The Columbine association added a layer of public suspicion that made the withdrawal feel more ominous than it was. But fluvoxamine has been continuously prescribed in the U.S. for over three decades, and its safety profile is well established and comparable to other SSRIs.